P
Philogen
Biotech & Life Sciences · Sovicille, Italy · Founded 1996
Develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders MoreLess
Philogen is a Swiss-Italian biotechnology company founded in 1996, specializing in the development of innovative biopharmaceuticals for treating angiogenesis-related disorders, which involve the formation of new blood vessels. The company operates in the biopharmaceutical market, focusing on the discovery, GMP production, and clinical development of targeted therapeutics, particularly antibody-based treatments. Philogen serves large pharmaceutical companies through numerous collaborative agreements and partnerships. Its business model revolves around the development and commercialization of proprietary therapeutics, generating revenue through licensing deals, milestone payments, and royalties. The company leverages its expertise in antibody engineering and targeted drug delivery to maintain a leading position in its field. Keywords: biopharmaceuticals, angiogenesis, antibody-based therapeutics, biotechnology, clinical development, GMP production, targeted therapeutics, pharmaceutical partnerships, drug discovery, innovative treatments.
Company overview
Philogen company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1996
- Headquarters
- Sovicille, Italy
- Employees
- 183
- Open positions
- 11
- Dealroom signal
- 83.9
Valuation & funding
Philogen funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Mar 2021 | $69M | $690M | Undisclosed | ↗ |
| LATE VCOther financing | May 2019 | $68M | $273M | The Equity Club · Mediobanca | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $346M | 0% | $288M | 83.2% |
| 2025 | $346M | +324.8% | $288M | 83.2% |
| 2024 | $81M | +219.9% | $47M | 57.8% |
| 2023 | $25M | -2.5% | −$5.3M | -21% |
| 2022 | $26M | +850% | $3.3M | 12.7% |
| 2021 | $2.7M | -47.8% | −$16M | -597.5% |
| 2020 | $5.3M | — | −$12M | -222.5% |
Growth signals
Philogen website traffic
Latest recorded traffic for Philogen is 5.3K monthly website visits, down 8.6% over the last three months. Philogen's team grew 8.3% over the past year.
Hiring
Open positions at Philogen
Current openings linked to this company in Dealroom.
Comparisons
Philogen compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Philogen's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Philogen's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Philogen has talent and traffic
team presence
In the news
Latest news about Philogen
Recent press, funding announcements, and product moves mentioning Philogen — open to read from the original sources.
Market sentiment
What the market is saying about Philogen
An AI-synthesized read of the highest-engagement posts about Philogen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Philogen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.